Now showing items 1-10 of 18
Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
(Health Aff (Millwood), 2014-06)
In March 2010 Congress established an abbreviated Food and Drug Administration approval pathway for biosimilars-drugs that are very similar but not identical to a reference biological product and cost less. Because bringing ...
Biosimilar competition: lessons from Europe
(Nature Reviews Drug Discovery, 2014-01-21)
An Economic Analysis of Global Policy Proposals to Prohibit Compensation of Blood Plasma Donors
(International Journal of the Economics of Business, 2016-05-03)
© 2016 International Journal of the Economics of Business.Human blood plasma and its derivative therapies have been used therapeutically for more than 50 years, after first being widely used to treat injuries during World ...
Implementation of the Biosimilar Pathway: Economic and Policy Issues
(Seton Hall Law Review, 2011)
Does generic entry always increase consumer welfare?
(Food Drug Law J, 2012)
This article examines how the nature of competition between brands in a therapeutic category changes after generic entry and provide a framework for analyzing the effect of generic entry on consumer welfare that takes into ...
The Evolution of the Pharmaceutical Industry Over the Past 50 Years: A Personal Reflection
(International Journal of the Economics of Business, 2011-07)
Innovation in the pharmaceutical industry: New estimates of R&D costs.
(J Health Econ, 2016-05)
The research and development costs of 106 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drug and biologics development. ...
Recent Trends in Brand-Name and Generic Drug Competition
(Journal of Medical Economics, 2013)
Mergers, Acquisitions, and Alliances
(The Oxford Handbook of the Economics of the Biopharmaceutical Industry, 2012-09-18)
© 2012 by Oxford University Press. All rights reserved.This article considers the determinants and effects of M&As in the pharmaceutical industry, with a particular focus on innovation and R&D productivity. As is the case ...
The roles of patents and research and development incentives in biopharmaceutical innovation.
(Health Aff (Millwood), 2015-02)
Patents and other forms of intellectual property protection play essential roles in encouraging innovation in biopharmaceuticals. As part of the "21st Century Cures" initiative, Congress is reviewing the policy mechanisms ...